|Bid||86.75 x 4800|
|Ask||87.40 x 100|
|Day's range||85.47 - 90.66|
|52-week range||17.33 - 111.36|
|PE ratio (TTM)||N/A|
|Earnings date||7 May 2018 - 11 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||97.50|
Nektar (NKTR) initiates dosing in a phase I/II study, evaluating the combination of its two novel immuno-oncology agents, NKTR-262 and NKTR-214, on patients with advanced solid tumors.
On Monday, April 2, 2018, CASI Pharmaceuticals (CASI) stock opened at $4.20. It grew ~68% over the week to close at $7.01 on April 6. Its 52-week low was $0.91 on June 20, 2017.
Key market index funds were lower Wednesday amid rising U.S.-Russia tension over Syria. But Netflix rallied ahead of earnings.
Last month, Nektar Therapeutics (NKTR) stock rose 25.7%, from $84.55 on March 1, 2018, to $106.26 on March 29, 2018. According to reports, Nektar Therapeutics has risen 78%, proving to be the best-performing stock in the S&P 500 in 1Q18. Since November 2017, the company has been on an upward trajectory, mainly due to positive results from the dose-escalation phase of the PIVOT-02 Phase 1/2 expansion study designed to evaluate the efficacy and safety of Nektar Therapeutics’ NKTR-214 in combination with Bristol-Myers Squibb’s (BMY) Opdivo in patients suffering with non-small cell lung cancer, renal cell carcinoma, and stage 4 melanoma.
A high-profile flop for a once-promising cancer drug in development at Incyte is sparking fear across the industry.
Medical Technology Stock Letter continues to find the future leaders of biotech and next-generation drug development. As we continue this search, we urge biotech investors to consider the Four Horsemen as potential investments, writes editor John McCamant and frequent MoneyShow.com contributor.
Humana (HUM) sped past the rest of the S&P 500 on its potential acquisition by Walmart (WMT). Humana gained $11.87, or 4.4%, to $280.70. The S&P 500 fell 58.99 points, or 2.23%, to 2581.88. News broke last week that Walmart was in talks with Humana, although it was after markets had closed for the Good Friday holiday.
Here are the 10 best-performing stocks in the S&P 500 in the first quarter: Nektar Therapeutics (NKTR) gained 77.9%. The biopharmaceutical firm is often cited as a potential takeover target, although the merits of its pipeline are also touted on their own, and its gains come on the heels of a very strong 2017, as well. Earlier this month, it replaced Chesapeake Energy (CHK) in the S&P 500. Netflix (NFLX) gained 53.9%.
Why Are Investors Excited about Nektar Therapeutics in 2018? Nektar Therapeutics (NKTR) generates revenues from collaboration agreements through which it receives product sales revenues, royalties, license fees, milestone payments, and contract research payments. In fiscal 2017, Nektar Therapeutics generated total revenues of $307.7 million compared with $165.4 million in fiscal 2016.
Why Are Investors Excited about Nektar Therapeutics in 2018? Nektar Therapeutics (NKTR) is a biopharmaceutical company with investigational drug candidates for the treatment of cancer, autoimmune disease, and chronic pain. Of the nine analysts covering Nektar Therapeutics in March 2018, four of them have given the stock a “strong buy” rating.
Take-Two Interactive Software Inc., SVB Financial Group and Nektar Therapeutics are joining the S&P 500 index, according to S&P Dow Jones Indices.